Aim: To evaluate the prognostic significance of lymph node metastasis, extent of examined lymph nodes (ELNs) and lymph node ratio (LNR) for resected pancreatic neuroendocrine neoplasms (pNENs).
INTRODUCTION
Pancreatic neuroendocrine neoplasms (pNENs), also known as pancreatic endocrine tumors, islet cell neoplasms or islet cell carcinomas, are rare tumors with an annual incidence of 0.19/100,000-0.32/100,000 [1] [2] [3] . However, compared to 1973, the incidence of NENs in 2004 has increased 382% in United States [3] . Although pNENs are associated with relatively indolent physiological behavior, most patients eventually succumb to mortality due to the disease [4, 5] .
Lymph node metastasis is commonly used as a critical prognostic factor for predicting survival and disease progression of pancreatic ductal adenocarcinomas (PDAC) and pNENs [6] [7] [8] [9] . However, some studies showed that lymph node metastasis was not an independent prognostic factor of PDAC and pNENs [10, 11] . The accuracy of staging lymph node was directly proportional to the number of examined lymph nodes (ELNs), and many studies suggested that the extent of ELNs was significantly associated with survival of PDAC, especially in patients without lymph node metastasis [12] [13] [14] . Moreover, lymph node ratio (LNR), the number of metastatic lymph nodes divided by the total number of ELNs, was increasingly recognized as a more powerful prognostic factor than lymph node metastasis in PDAC [10, 11, 15] , intraductal papillary mucinous [16] , and ampullary carcinoma [17, 18] .
However, the benefit of ELNs in pNENs is still unclear; and the role of LNR in predicting survival is contradictory. Boninsegna et al. [19] and Ricci et al. [20] proposed that LNR > 0.20 and LNR > 0.07, respectively, was the robust predictor of recurrence of pNENs. On the other hand, Murakami et al. [8] found that LNR > 0.20 did not correlate with poor overall survival (OS). These contradictory results might be attributed to the relative rarity of the samples and the cut-off values of LNR in these studies, which limited the identification of LNR in survival.
The Surveillance, Epidemiology, and End Results (SEER) database is an authoritative source of information with high-quality cancer registries, established in 1973, encompassing approximately 28% of the USA population. All the malignant cases were followed-up annually to determine the vital status. The large population and completed follow-up of SEER program can be safely speculated to represent the total USA population.
The aim of the present study was to use a large population to evaluate the predictive role of ELNs, lymph node metastasis, and LNR in OS of pNENs after surgical resection. Furthermore, we attempted to establish the correlation between LNR and clinicopathological characteristics (tumor size, grade, and stage).
RESULTS

Patients' characteristics
A total of 1,273 pathologically confirmed pNENs comprising of 680 males and 593 females, were included in our study (Figure 1 ). The median age and interquartile range (IQR) at diagnosis were 58 years (49 years-67 years). Approximately, 80% patients were ethnically Caucasians. The degree of tumor localized at the head was similar to that of the tail (32.8% and 36.8% of all patients, respectively, head-to-tail ratio, 0.89:1). Approximately, 60.0% of patients underwent partial pancreatectomy. The tumor size in 73.0% patients was larger than 2.0 cm. The median of ELNs was 10 (IQR, 5-16), and 42.0% patients with lymph node metastasis. The median of LNR was 0 (IQR, 0-0.2); 61.6% patients exhibited SEER grade I. The proportion of AJCC TNM stage I and stage II were 38.7% and 40.3%, respectively ( Table 1) .
The lymph node metastasis and overall survival
As we assumed, the OS of the patients with lymph node metastasis (82.965 months ± 2.504 months) was significantly (P < 0.001) shorter than that of patients without metastasis (97.615 months ± 2.086 months) ( Figure 2A ). The univariate analysis showed the lymph node metastasis significantly (P < 0.001) increased the risk of death (HR 1.914, 95% CI: 1.467-2.497). However, the multivariate analysis failed to display that the lymph node metastasis was associated with OS ( Table 2 ).
The extent of examined lymph nodes and overall survival
The most appropriate cut-off value of ELNs for entire cohort and the patients without lymph node metastasis were 12 and 28, respectively. Surprisingly, we found that the extent of ELNs was not a significantly beneficial survival factor in either entire cohort (ELNs ≤ 12 vs. ELNs > 12, 92.363 months ± 1.978 months vs. 85.285 months ± 2.582 months, P = 0.072) ( Figure 2B ) or in patients without lymph node metastasis (ELNs ≤ 28 vs. ELNs > 28, 98.231 months ± 2.106 months vs. 72.246 months ± 9.734 months, P = 0.108) ( Figure 2C ).
The lymph node ratio and overall survival
The most appropriate cut-off value of LNR was 0.40 in our study; and we found that compared to the OS of patients with LNR = 0 (97.615 months ± 2.086 months) and 0 < LNR ≤ 0.40 (86.468 months ± 3.006 months), LNR > 0.40 exhibited significantly (P < 0.001; P = 0.025; respectively) shorter OS (75.473 months ± 4.287 months) ( Figure 3A) . The multivariate analysis showed that LNR > 0.40 was an independent prognostic factor (HR = 1.650, 95% CI: 1.117-2.438, P = 0.012) ( Table 2) .
We also evaluated the predictive role of LNR > 0.2 and LNR > 0.07 reported by Boninsegna et al. [19] and Ricci et al. [20] , respectively. We found that compared to the OS of patients with LNR= 0 (97.615 months ± 2.086 months), patients with LNR > 0.2 and LNR > 0.07 presented significantly (both P < 0.001) shorter OS (81.004 months ± 3.257 months and 82.245 months ± 2.648 months, respectively) ( Figure 3B and 3C ). The univariate analysis demonstrated that LNR > 0.20 and LNR > 0.07 significantly (both P < 0.001) increased the risk of death (HR = 2.095, 95% CI: 1.561-2.812 and HR = 1.962, 95% CI: 1.496-2.574, respectively). However, the multivariate analysis failed to show that LNR > 0.20 and LNR > 0.07 were associated with OS (Supplementary Table 1 ).
The independent prognostic factors and predictive power
Besides LNR > 0.40, the multivariate analysis also confirmed that age > 60 years (P < 0.001), advanced SEER grade (grade III, P < 0.001; grade IV, P = 0.008) and AJCC TNM staging (stage III, P = 0.008; stage IV, P < 0.001) were the adverse predict factors of OS in pNENs; and female (P = 0.003), tumor located in body (P = 0.008) or tail (P = 0.031) were the beneficial factors. This prognosis model (age, gender, tumor primary site, SEER grade, AJCC TNM staging and LNR) had acceptable discrimination (Harrell's concordance index, 0.731, 95% CI: 0.689-0.773); and it was significantly better than SEER grade (Harrell's concordance index, 0.636, 95% CI: 0.597-0.676) or AJCC TNM staging (Harrell's concordance index, 0.636, 95% CI: 0.599-0.673).
The LNR and clinicopathological characteristics
The Spearman's rank correlation showed a high LNR was positive correlated with an advanced AJCC TNM staging (r s = 0.604, P < 0.001). Similarly, the higher LNR showed positive correlation with bigger tumor size (r s = 0.273, P < 0.001) and advanced SEER grade (r s = 0.136, P < 0.001) ( Table 3) .
DISCUSSION
Currently, the AJCC and the European Neuroendocrine Tumor Society staging classification use the regional lymph node metastasis as a prognostic indicator of pNENs [21] . However, several studies proved contrary conclusions [22] [23] [24] [25] . The conflicting results may be due to the incomplete lymphadenectomy or inadequate histopathological examination [26] . As the total number of ELNs rises, the number of metastatic lymph nodes also rises; and previous study demonstrated the number of ELNs were associated with the accuracy of lymph node staging and OS in PDAC, especially in patients without lymph node metastasis [15] . Thus, the International Study Group on Pancreatic Surgery recommended that at least 12 lymph nodes should be examined for PDAC [27] .
In the present study, we only included patients underwent lymphadenectomy and the median of ELNs was 10 (IQR, 5-16). The most appropriate cut-off value of ELNs for entire cohort and pNENs without lymph node metastasis were 12 and 28, respectively. Surprisingly, we found the extent of ELNs failed to demonstrate any survival benefit in entire cohort (ELNs > 12 vs. ELNs ≤ 12) or in the negative lymph node metastasis pNENs (ELNs > 28 vs. ELNs ≤ 28). Similar to our findings, Conrad et al. [28] also demonstrated that the extent of ELNs (ELNs ≥ 10) failed to show significant survival advantage.
As mentioned by previous studies [7, 8] , we also found the OS of pNENs with lymph node metastasis (82.965 months ± 2.504 months) was significantly (P < 0.001) shorter than that of pNENs without lymph node metastasis (97.615 months ± 2.093 months). Moreover, the lymph node metastasis significantly (P < 0.001) increased the risk of death (HR = 1.914; 95% CI: 1.467-2.497). However, the multivariate analysis failed to show lymph node metastasis was an independent prognostic factor in pNENs.
Recently, LNR has been demonstrated as a superior prognostic parameter than lymph node metastasis in PDAC [10, 11, 15] , bladder [29] , esophageal [30] , and colon cancers [31] . Boninsegna et al. [19] and Ricci et al. [20] also demonstrated that LNR was an independent prognostic factor of recurrence in pNENs. However, Murakami et al. [8] reported LNR was not an independent prognostic factor of OS in pNENs.
We included 1,273 pathologically confirmed pNENs in our study and the most appropriate cut-off value of LNR was 0.40. The Kaplan-Meier and log-rank test demonstrated the OS of pNENs with LNR > 0.40 (75.473 months ± 4.287 months) was significantly shorter than that of pNENs with LNR = 0 (97.615 months ± 2.086 months, P < 0.001) and 0 < LNR ≤ 0.40 (86.468 months ± 3.006 months, P = 0.025), respectively; not only the univariate analysis but also the multivariate analysis showed LNR was an independent prognostic factor. To our knowledge, the present study is the largest population-based study to assess the OS benefit of LNR in pNENs.
Ricci et al. [20] and Boninsegna et al. [19] reported LNR > 0.07 and LNR > 0.20 were independent adverse predictors of recurrence, respectively. However, they did not discuss the relationship between LNR and OS. We found that compared to LNR = 0, LNR > 0.07 and LNR > 0.20 also significantly (both P < 0.001) increased the risk of death (HR = 1.962, 95% CI: 1.496-2.574; HR = 2.095, 95% CI: 1.561-2.812, respectively). However, the multivariate analysis failed to show LNR > 0.07 or LNR > 0.20 was an independent prognostic factor of OS. Our findings were consistent with those of Murakami et al. [8] . The authors reviewed the records of 119 consecutive patients with pancreatic ductal carcinoma and they also found LNR > 0.2 was not an independent prognostic factor of OS.
In contrast to pNENs, several studies had demonstrated LNR > 0.2 was an independent negative prognostic factor of OS in PDAC [32, 33] . The contradictory results can notably be explained by the relatively indolent physiological behavior of pNENs. pNENs are characterized by long term survival, even if 
Besides LNR > 0.40, age older than 60 years, advanced AJCC stage, and SEER grade, the multivariate Cox regressions also demonstrated that male and primary tumor located in pancreatic head were associated with poor outcome. This is probably due to that the carcinoid syndrome was more frequently in female patients; and this increased the likelihood of diagnosis and surgical treatment in the early lesions for female patients [34] . Hashim et al. [35] reported that compared to pancreas body or tail, the head was more likely associated with lymph node metastasis; and this can explain the adverse prognostic role of primary tumor located in pancreas head.
We also found that the higher LNR was positively correlated with bigger tumor size, advanced AJCC stage, and SEER grade. To our knowledge, this is the first study to investigate the correlation between LNR and clinicopathological features. Notably, there were several limitations to our study. First, due to the constraints of the SEER database, we failed to evaluate the role of Ki-67, mitotic index, lymphovascular invasion, resection margin in OS. Second, this was a retrospective study; thus, the selection bias was inevitable.
In summary, our study demonstrated that it was LNR, not the number of ELNs or lymph node metastasis, proved to be an independent prognostic indicator. In the future, it is better to take into account the LNR for the pNENs staging classification; and further prospective study is needed to determine these findings.
MATERIALS AND METHODS
Patient population
To identify the pancreatic tumor, the topography codes (C25 Pancreas, C25.0-C25.9) of International Classification of Diseases for Oncology, Third Edition 
Inclusion and exclusion criteria
Only patients microscopically diagnosed as pNENs and underwent surgical resection were included. Cases without precise data for the following variables were excluded: race, tumor size, the number of lymph node metastasis or ELNs, and AJCC TNM staging. Large cell neuroendocrine carcinoma (ICD-O-3, 8013) and small cell carcinoma (ICD-O-3, 8041) mostly originating from lung were also excluded [3] .
Outcome and variables
The primary outcome was OS and the following variables were considered as potential prognostic factors of OS: age; gender (male and female); race (white, black. other: American Indian/AK Native, Asian/Pacific Islander and unknown); primary tumor site (head, body, tail, other: islets of Langerhans, other specified parts of pancreas, overlapping lesion of pancreas, not otherwise specified); surgical procedures (enucleation, partial pancreatectomy, total pancreatectomy, whipple, surgery not otherwise specified); tumor size; lymph node metastasis; ELNs; LNR; SEER grade and AJCC TNM staging (sixth edition).
Not all of the SEER registries reported tumor grade according to the WHO 2010 classification [36] . Therefore, SEER database used four tumor grades based on the basis of morphological description (ICD-O-3) in pathology report: SEER grade I including tumors classified as well differentiated; grade II including those classified as moderately differentiated; grade III including those classified as poorly differentiated, and grade IV including those classified as undifferentiated or anaplastic [34] .
The cut-off value of continuous variables
Age and tumor size were defined as two-category variable according to previous studies: age ≤ 60 years vs. age > 60 years [23] ; tumor size ≤ 2 cm vs. tumor size > 2 cm [8] . The cut-off value of ELNs and LNR were determined according to the Youden's index [37] ; and the ELNs were also analyzed as two-categories. We hypothesized that the lymph node metastasis was a prognostic factor of OS. Thus, the LNR was analyzed in three categories (LNR = 0, LNR between 0 and cut-off value; LNR > cut-off value) and then it was also analyzed according to the cut-off value of 0.07 and 0.20 reported by Ricci et al. [20] and Boninsegna et al. [19] , respectively.
Data analysis and statistics
The continuous non-normal distribution variables were expressed as median and IQR, and the categorical or ordinal variables were presented as frequencies and proportions. The OS was analyzed using the Kaplan-Meier and log-rank tests and presented as mean ± standard deviation. Univariate (enter) and multivariate (forward stepwise regression) Cox proportional hazards models were used to identify the independent factors associated with OS. The Harrell's concordance index was used to evaluate the combined predictive power of all independent prognostic factors [38] . If the value is more than 0.70, it can be concluded that the model has an acceptable discriminatory capability [39] . Spearman's rank correlation coefficient, r s , was used to quantify the correlation between LNR and clinicopathological characteristics. r s ranged from −1 to +1, where −1 indicates a perfect negative association of ranks, zero indicates no association between ranks and +1 refers to a perfect association of ranks. All statistical analyses were performed using SPSS version 19.0 (IBM Corporation. Armonk, NY, USA). P-value ≤ 0.05 was considered statistically significant.
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